The GLP-1 medication is now available via injection and pill.

Wegovy tablets offer a daily oral alternative to injections for weight reduction and reducing cardiovascular risk in eligible adult patients.

Does the new Wegovy pill work as well as Wegovy injections for weight loss? How else does it compare? Learn what the experts ...

Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

While injectable medications have dominated the weight loss space for years, most people aren’t exactly pumped to stick a needle in their stomach on a weekly basis. Now, a potential game-changing ...

FDA has approved Novo Nordisk's once daily oral Wegovy pill for obesity and cardiovascular risk reduction, and the product has now launched in the U.S. The oral format offers an alternative to ...

A NEW jab set to rival the likes of Mounjaro and Wegovy helped people lose up to 22 per cent of their body weight in less ...

Danish drugmaker Novo Nordisk said the first-of-its kind oral pill will offer 1.5 and 4 milligram doses at $149 per month for ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Novo Nordisk (NVO) stock is in focus as the Wegovy pill tops 3,071 U.S. scripts in the first 4 days of its launch. Read more ...